Across multiple tumor models, sinensetin suppresses oncogenic signaling-including β-catenin, PI3K/AKT, VEGF, NRF2, P53, and MKK6-concomitant with reduced proliferation, migration, and survival signaling. The gene discussed is MAP2K6; the disease is neoplasm.